883 related articles for article (PubMed ID: 9205822)
1. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
3. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Crewe HK; Lennard MS; Tucker GT; Woods FR; Haddock RE
Br J Clin Pharmacol; 1992 Sep; 34(3):262-5. PubMed ID: 1389951
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
Schmider J; Greenblatt DJ; von Moltke LL; Karsov D; Shader RI
Br J Clin Pharmacol; 1997 Nov; 44(5):495-8. PubMed ID: 9384467
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
von Moltke LL; Greenblatt DJ; Court MH; Duan SX; Harmatz JS; Shader RI
J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
Riesenman C
Pharmacotherapy; 1995; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
[TBL] [Abstract][Full Text] [Related]
7. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
8. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
11. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
[TBL] [Abstract][Full Text] [Related]
14. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of imipramine metabolism by human liver microsomes.
Skjelbo E; Brøsen K
Br J Clin Pharmacol; 1992 Sep; 34(3):256-61. PubMed ID: 1389950
[TBL] [Abstract][Full Text] [Related]
17. Reducing the risk of drug-drug interactions: a goal of rational drug development.
Preskorn SH
J Clin Psychiatry; 1996; 57 Suppl 1():3-6. PubMed ID: 8617709
[No Abstract] [Full Text] [Related]
18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Nelson MH; Birnbaum AK; Remmel RP
Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
[TBL] [Abstract][Full Text] [Related]
20. Drug-drug interactions.
Preskorn SH
J Clin Psychiatry; 1996 May; 57(5):223-7. PubMed ID: 8626354
[No Abstract] [Full Text] [Related]
[Next] [New Search]